Work

Cost‐utility of sirolimus in the treatment of vascular malformations

Year: 2024

Type: article

Abstract: Sirolimus is being increasingly employed to manage specific vascular anomalies. We performed an exploratory cost-utility analysis to evaluate sirolimus as a treatment for vascular malformations from the Australian healthcare system perspective. Over a one-year time horizon, sirolimus treatment was associated with an increased expenditure of AU$2832.80 and a gain of 0.08 quality-adjusted life years (QALYs) when compared to supportive care, resulting in an incremental cost-effectiveness ratio of AU$35,410/QALY. By most metrics, sirolimus would be considered a cost-effective treatment for vascular malformations.

Source: Australasian Journal of Dermatology

DOI: 10.1111/ajd.14369

Authors: Grace Xiaoying Li, Deshan Frank Sebaratnam

Institutions: Liverpool Hospital, UNSW Sydney

Language: English

Topic: Vascular Malformations and Hemangiomas

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,960